Personalizing therapy for inflammatory bowel diseases

References

• Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54.e42; quiz e30 (2012).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140, 1785–1794 (2011).
   PubMed Web of Science ®Google Scholar
• Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am. J. Gastroenterol. 103, 3167–3182 (2008).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 135, 1907–1913 (2008).
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm. Bowel Dis. 19, 37–44 (2013).
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412–422 (2007).
   PubMed Web of Science ®Google Scholar
• Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr. Gastroenterol. Rep. 12, 471–478 (2010).
   PubMedGoogle Scholar
• Laharie D, Filippi J, Roblin X et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment. Pharmacol. Ther. 37(10), 998–1004 (2013).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. The future of inflammatory bowel disease therapy: where do we go from here? Dig. Dis. 30(Suppl. 3), 140–144 (2012).
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Gastroenterol. Clin. North Am. 38, 691–709 (2009).
   PubMed Web of Science ®Google Scholar
• Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol. Clin. North Am. 38, 669–689 (2009).
   PubMedGoogle Scholar
• Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 306, 2331–2339 (2011).
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am. J. Gastroenterol. 106, 674–684 (2011).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104, 760–767 (2009).
   PubMed Web of Science ®Google Scholar
• Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 5, 597–601 (2007).
   PubMedGoogle Scholar
• Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm. Bowel Dis. 13, 1529–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54, 237–241 (2005).
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Golovics PA, David G et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977–2009. Am. J. Gastroenterol. 107, 579–588 (2012).
   PubMed Web of Science ®Google Scholar
• Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59, 1200–1206 (2010).
   PubMed Web of Science ®Google Scholar
• Camus M, Seksik P, Bourrier A et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin. Gastroenterol. Hepatol. 11, 389–394 (2013).
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Seow CH, Ghosh S et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am. J. Gastroenterol. 107, 1879–1887 (2012).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am. J. Gastroenterol. 107, 1228–1235 (2012).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J. Gastrointest. Surg. 15, 267–276 (2011).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8, 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 25, 665–672 (1984).
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44, 431–440 (2009).
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 130, 650–656 (2006).
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. 43, 948–954 (2008).
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139, 1147–1155 (2010).
   PubMed Web of Science ®Google Scholar
• Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract. Res. Clin. Gastroenterol. 18, 481–496 (2004).
   PubMed Web of Science ®Google Scholar
• Cosnes J. What is the link between the use of tobacco and IBD? Inflamm. Bowel Dis. 14(Suppl. 2), S14–S15 (2008).
   PubMedGoogle Scholar
• Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 120, 1093–1099 (2001).
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment. Pharmacol. Ther. 35, 625–633 (2012).
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig. Liver Dis. 44, 453–460 (2012).
   PubMedGoogle Scholar
• Swoger JM, Regueiro M. Preventive therapy in postoperative Crohn's disease. Curr. Opin. Gastroenterol. 26, 337–343 (2010).
   PubMedGoogle Scholar
• Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 98, 1123–1128 (1990).
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J. Gastroenterol 11, 3971–3979 (2005).
   PubMed Web of Science ®Google Scholar
• Aeberhard P, Berchtold W, Riedtmann HJ, Stadelmann G. Surgical recurrence of perforating and nonperforating Crohn's disease. A study of 101 surgically treated Patients. Dis. Colon. Rectum. 39, 80–87 (1996).
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Lachman P, Sachar DB et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 29, 588–592 (1988).
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm. Bowel Dis. 12, 543–550 (2006).
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317 (2011).
   PubMed Web of Science ®Google Scholar
• Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig. Dis. 28, 418–423 (2010).
   PubMed Web of Science ®Google Scholar
• Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm. Bowel Dis. 18, 1872–1884.
   PubMedGoogle Scholar
• Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J. Gastroenterol. 13, 2028–2036 (2007).
   PubMed Web of Science ®Google Scholar
• Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 18, 1340–1355 (2012).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lin YC, Dutridge D et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterol. 101, 360–367 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Targan SR, Dubinsky MC et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm. Bowel Dis. 17, 2488–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126, 414–424 (2004).
   PubMed Web of Science ®Google Scholar
• Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am. J. Gastroenterol. 101, 645–652 (2006).
   PubMed Web of Science ®Google Scholar
• Desir B, Amre DK, Lu SE et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Papp M, Rieder F. Serologic antiglycan antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 106, 406–412 (2011).
   PubMed Web of Science ®Google Scholar
• Rieder F, Schleder S, Wolf A et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm. Bowel Dis. 16, 1367–1375 (2010).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin. Proc. 71, 431–436 (1996).
   PubMed Web of Science ®Google Scholar
• Fleshner PR, Vasiliauskas EA, Kam LY et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49, 671–677 (2001).
   PubMed Web of Science ®Google Scholar
• Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, LaMorte W, Farraye FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J. Gastrointest. Surg. 10, 1060–1064 (2006).
   PubMedGoogle Scholar
• Fleshner P, Ippoliti A, Dubinsky M et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 6, 561–568 (2008).
   PubMed Web of Science ®Google Scholar
• Tyler AD, Milgrom R, Xu W et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 10, 507.e1–512.e1 (2012).
   Google Scholar
• Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422), 119–124 (2013).
   Google Scholar
• Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 106, 699–712 (2011).
   PubMed Web of Science ®Google Scholar
• Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123, 679–688 (2002).
   PubMed Web of Science ®Google Scholar
• Alvarez-Lobos M, Arostegui JI, Sans M et al. Crohn's disease patients carrying NOD2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242, 693–700 (2005).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Collins N, Maresso K et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 1003–1009 (2004).
   PubMedGoogle Scholar
• Latiano A, Palmieri O, Cucchiara S et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am. J. Gastroenterol. 104, 110–116 (2009).
   PubMed Web of Science ®Google Scholar
• Duraes C, Machado JC, Portela F et al. Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm. Bowel Dis. 19(2), 230–239 (2012).
   Google Scholar
• Henckaerts L, Van Steen K, Verstreken I et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin. Gastroenterol. Hepatol. 7, 972–980.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Sehgal R, Berg A, Polinski JI et al. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohn's disease. Dis. Colon Rectum. 55, 115–121 (2012).
   PubMed Web of Science ®Google Scholar
• Weersma RK, Stokkers PC, van Bodegraven AA et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 58, 388–395 (2009).
   PubMed Web of Science ®Google Scholar
• Daniel F, Loriot MA, Seksik P et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm. Bowel Dis. 13, 19–23 (2007).
   PubMedGoogle Scholar
• Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 5, 530–539 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto-Furusho JK, Villeda-Ramirez MA, Fonseca-Camarillo G et al. High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm. Bowel Dis. 16, 541–542 (2010).
   PubMed Web of Science ®Google Scholar
• Annese V, Piepoli A, Latiano A et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum. 48, 57–64; discussion 64–65 (2005).
   PubMed Web of Science ®Google Scholar
• Haritunians T, Taylor KD, Targan SR et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm. Bowel Dis. 16, 1830–1840 (2010).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. 95, 3189–3194 (2000).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am. J. Gastroenterol. 105, 1574–1582 (2010).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136, 441–450.e1; quiz 716 (2009).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therap. Adv. Gastroenterol. 2, 245–251 (2009).
   PubMedGoogle Scholar
• Esters N, Vermeire S, Joossens S et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97, 1458–1462 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120, 1347–1355 (2001).
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment. Pharmacol. Ther. 31, 92–101 (2010).
   PubMed Web of Science ®Google Scholar
• Dideberg V, Louis E, Farnir F et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics 16, 369–373 (2006).
   PubMed Web of Science ®Google Scholar
• Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. 105, 1811–1819.
   PubMedGoogle Scholar
• Louis E, El Ghoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19, 511–519 (2004).
   PubMed Web of Science ®Google Scholar
• Louis E, Vermeire S, Rutgeerts P et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818–824 (2002).
   PubMed Web of Science ®Google Scholar
• Louis EJ, Watier HE, Schreiber S et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet. Genomics 16, 911–914 (2006).
   PubMed Web of Science ®Google Scholar
• Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 12, 509–515 (2002).
   PubMedGoogle Scholar
• Pierik M, Vermeire S, Steen KV, Joossens S et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. 20, 303–310 (2004).
   PubMed Web of Science ®Google Scholar
• Urcelay E, Mendoza JL, Martinez A et al. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J. Gastroenterol. 11, 1187–1892 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Rutgeerts P et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123, 106–111 (2002).
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm. Bowel Dis. 13, 372–379 (2007).
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Pierik M, Henckaerts L et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613–626 (2005).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Mei L, Friedman M et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1357–1366 (2010).
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, Quintens R et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Arijs I, Quintens R, Lommel LV et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 16(12), 2090–2098 (2010).
   PubMed Web of Science ®Google Scholar
• Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130, 1047–1053 (2006).
   PubMed Web of Science ®Google Scholar
• Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am. J. Gastroenterol. 103, 3115–3122 (2008).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122, 904–915 (2002).
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am. J. Gastroenterol. 108, 40–47; quiz 48 (2013).
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 1133–1139 (2010).
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol. 108(6), 962–971 (2013).
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11, 444–447 (2013).
   PubMed Web of Science ®Google Scholar
• Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 35, 15–36 (2012).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am. J. Gastroenterol. 107, 1051–1063 (2012).
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Desai A, Zator ZA, de Silva P et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19, 309–315 (2013).
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9, 30–35 (2011).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am. J. Gastroenterol. 107, 1051–1063 (2012).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68, 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7, 874–881 (2009).
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9, 36–41.e1 (2011).
   PubMed Web of Science ®Google Scholar